A double-blind, randomized, placebo-controlled, multi-center, dose escalation study of a single intravenous infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in the treatment of biologic-naive patients with rheumatoid arthritis
Latest Information Update: 28 Sep 2018
At a glance
- Drugs Rexlemestrocel-L (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Mesoblast
- 26 Sep 2018 This trial has been discontinued in Estonia.
- 14 Feb 2013 New trial record